---
title: "Viatris gains as UBS upgrades to buy on outlook and pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275354256.md"
description: "Shares of Viatris (VTRS) rose after UBS upgraded the stock to Buy from Neutral, increasing the price target from $8 to $11 per share. Analyst Ashwani Verma highlighted a positive growth outlook and a robust drug pipeline, adjusting estimates accordingly. He noted Viatris trades at a favorable valuation of 5x consensus EPS estimates for 2027. Overall, Wall Street maintains a bullish stance on Viatris, with an average analyst rating of Buy, while Seeking Alpha rates it as a Hold."
datetime: "2026-02-09T19:03:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275354256.md)
  - [en](https://longbridge.com/en/news/275354256.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275354256.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275354256.md) | [繁體中文](https://longbridge.com/zh-HK/news/275354256.md)


# Viatris gains as UBS upgrades to buy on outlook and pipeline

Shares of Viatris (VTRS) traded higher on Monday after UBS upgraded the company to Buy from Neutral and lifted its price target to $11 from $8 per share, citing a promising growth outlook and a growing pipeline of drugs. Analyst Ashwani Verma hiked his estimates for the company, noting, “We layer in new product cycle pipeline & maintain potential c...

### Related Stocks

- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [Viatris Inc. (VTRS.US)](https://longbridge.com/en/quote/VTRS.US.md)

## Related News & Research

- [Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research](https://longbridge.com/en/news/278908205.md)
- [A Look At Viatris (VTRS) Valuation After Earnings, 2026 Guidance And MR-141 FDA Review](https://longbridge.com/en/news/277640565.md)
- [Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy](https://longbridge.com/en/news/278644625.md)
- [Pfizer's eczema drug meets main goal in mid-stage trial, plans late-stage study](https://longbridge.com/en/news/278381816.md)
- [EXCLUSIVE: Scienture Expands Reach For Opioid Overdose Treatment, With Deals Covering 60% Of US Institutional Market](https://longbridge.com/en/news/278715508.md)